Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study

The IMPEDE VTE score has recently emerged as a novel risk prediction tool for venous thromboembolism (VTE) in multiple myeloma (MM). We retrospectively reviewed 839 patients with newly diagnosed MM between 2010 and 2015 at Cleveland Clinic and included 575 patients in final analysis to validate this score. The c-statistic of the IMPEDE VTE score to predict VTE within 6 months of treatment start was 0 center dot 68 (95% CI: 0 center dot 61-0 center dot 75). The 6-month cumulative incidence of VTE was 5 center dot 0% (95% CI: 2 center dot 1-7 center dot 9) in the low risk group, compared to 12 center dot 6% (95% CI: 8 center dot 9-16 center dot 4%) and 24 center dot 1% (95% CI: 12 center dot 2-36 center dot 1) in the intermediate and high risk groups (P < 0 center dot 001 for both). In addition, a higher proportion of patients in the VTE cohort had ECOG performance status of >= 2 as compared to the no VTE cohort (33% vs. 16%, P = 0 center dot 001). Other MM characteristics such as stage, immunoglobulin subtype, and cytogenetics were not predictors of VTE. In summary, we have validated the IMPEDE VTE score in our patient cohort and our findings suggest that it can be utilized as a VTE risk stratification tool in prospective studies looking into investigating VTE prophylaxis strategies in MM patients.

Automated summary

The IMPEDE VTE score is a novel risk prediction tool for venous thromboembolism in multiple myeloma patients, with validated predictive ability for VTE occurrence within 6 months. The study found that patients in the low risk group had lower incidence of VTE, while those in the intermediate and high risk groups had higher rates, and a higher ECOG performance status was associated with VTE occurrence. Other MM characteristics such as stage, immunoglobulin subtype, and cytogenetics were not predictors of VTE.